| Topic | EP 12th Edition UDCA Monograph Compliance |
|---|---|
| Effective Date | 1 January 2026 |
| UDCA Monograph | 1275 (Revised) |
| Classification | Case A — No data submission required |
| Supplement 12.3 | No UDCA changes (1 July 2026) |
| Target Audience | CEP holders, regulatory affairs, API buyers, QA/QC |
| Key Standards | Ph. Eur. 12th Edition, EDQM CEP 2.0, CESP |
The European Pharmacopoeia 12th Edition took effect on 1 January 2026, bringing a revised monograph for ursodeoxycholic acid (UDCA) — monograph 1275. For CEP holders and pharmaceutical buyers sourcing UDCA API for the European market, understanding what changed, what Case A classification means in practice, and how CEP 2.0 affects compliance is essential to maintaining regulatory standing. This guide explains each requirement, provides a timeline of key dates, and includes a practical verification checklist for API procurement teams.
The Ph. Eur. 12th Edition, effective 1 January 2026, includes a revised monograph for ursodeoxycholic acid (1275). While the core quality parameters remain largely consistent with the previous edition, the revision reflects the European Pharmacopoeia Commission's ongoing harmonization efforts and updates to general methods referenced within the monograph.
Key aspects of the revision include:
Supplement 12.3 Update (1 July 2026): The EDQM published Supplement 12.3 to the Ph. Eur. 12th Edition on 1 July 2026. UDCA monograph 1275 is not listed among the revised monographs in this supplement. This means no further monograph changes are expected for UDCA until at least Ph. Eur. Supplement 12.4 or later editions, likely not before 2027. CEP holders can plan revisions with confidence that the 12th Edition requirements are stable for the foreseeable future.
The EDQM classifies each revised monograph into one of several categories based on the impact on CEP dossiers. For UDCA monograph 1275, the classification is Case A — the most straightforward category.
Case A classification signifies that the monograph revision does not require CEP holders to submit any new data to the EDQM. The changes are editorial, clarificatory, or limited to updated cross-references to general methods — they do not affect the chemical-pharmaceutical data contained in the CEP dossier.
Specifically, Case A means:
Case A does not mean "do nothing." CEP holders have obligations under their quality management system:
Suppose your CEP dossier states: "The substance complies with the requirements of the current edition of the European Pharmacopoeia monograph for Ursodeoxycholic Acid." In this case, you must implement the 12th Edition specification now and update your batch release testing accordingly. If audited, you should be able to show that the new specification is in use.
If instead your dossier states: "Assay: 99.0% to 101.0% (HPLC, anhydrous basis) per Ph. Eur. 10th Edition monograph 1275," you should update the reference at the next CEP revision.
Running parallel to the Ph. Eur. 12th Edition changes is the ongoing rollout of CEP 2.0, the EDQM's redesigned Certificate of Suitability format introduced in September 2023. While CEP 2.0 is not tied to any specific pharmacopoeia edition, its implementation timeline overlaps significantly with the 12th Edition transition.
| Feature | Previous CEP Format | CEP 2.0 |
|---|---|---|
| Specification | Not always included with the certificate; often obtained separately | Full substance specification included as a CEP annex — part of the certificate itself |
| Letter of Access | Sometimes integrated with the CEP | Issued as a separate document, independent of the certificate |
| eCTD Submissions | Legacy validation criteria | New eCTD validation requirements effective 1 November 2025 |
| CESP Platform | Standard submission fields | New mandatory fields (CEP dossier number, substance name) for regulatory activities as of October 2025 |
The most significant practical change for API buyers is the CEP annex. Under CEP 2.0, the full specification is attached to the certificate. This means buyers can now directly compare the supplier's batch Certificate of Analysis (CoA) against the official CEP specification without requesting a separate document. This is a major transparency improvement that simplifies supplier qualification.
For CEP holders, the new format means ensuring that eCTD submissions pass the updated validation rules (effective November 2025) and that CESP submissions include the new mandatory fields (effective October 2025). Non-compliance with these technical requirements can delay submission processing.
The CEP 2.0 rollout remains ongoing in mid-2026. Not all CEPs have been converted — the EDQM is processing conversions progressively. When verifying a supplier, check whether the CEP is in the 2.0 format. A CEP still in the legacy format is not necessarily non-compliant, but it may indicate that the holder has not submitted a recent revision.
For pharmaceutical procurement and QA professionals sourcing UDCA API for the European market, here is a focused four-point verification checklist. Each point addresses a specific regulatory risk.
| # | Verification Point | What to Ask the Supplier | What to Look For | Red Flag |
|---|---|---|---|---|
| 1 | Ph. Eur. 12th Edition Reference | "Does your UDCA CEP reference the current Ph. Eur. 12th Edition?" | CEP certificate or annex should state compliance with Ph. Eur. 12th Edition monograph 1275 | CEP still references Ph. Eur. 10th or 11th Edition with no revision submitted since January 2026 |
| 2 | CEP 2.0 Format | "Is your CEP in the CEP 2.0 format?" | Certificate includes a specification annex; Letter of Access is a separate document | No specification annex available; supplier reluctant to share the full CEP document |
| 3 | Last Revision Date | "When was your last CEP revision submitted to the EDQM?" | Revision date should be after 1 January 2026, reflecting 12th Edition compliance, OR a documented plan for the next revision | Last revision predates 2022; no planned revision on file; supplier cannot confirm when next revision will be submitted |
| 4 | CoA vs. CEP Annex Alignment | "Please provide a recent batch CoA and the CEP specification annex for cross-reference." | All CoA specification limits must match or be tighter than the CEP annex. Assay, related substances, residual solvents must align. | CoA shows limits that are wider than those in the CEP annex; CoA omits parameters listed in the annex; specification discrepancies between documents |
Beyond these four core checks, buyers should also confirm that the supplier's GMP certificate is current, that the manufacturing site address is consistent across all documents (CoA, CEP, GMP certificate), and that the supplier can provide a recent regulatory inspection history.
The following timeline summarizes the key dates CEP holders and API buyers should track for UDCA monograph compliance.
| Date | Event | Impact on UDCA CEP |
|---|---|---|
| September 2023 | CEP 2.0 format introduced by EDQM | New CEPs and renewals begin using 2.0 format. Specification annex becomes standard. |
| 1 January 2026 | Ph. Eur. 12th Edition becomes effective | Revised UDCA monograph 1275 (Case A) takes effect. CEP holders must update internal specifications; no data submission to EDQM required. |
| 1 July 2026 | Supplement 12.3 published | UDCA NOT listed among revised monographs. No further changes expected until at least 2027. Confirmed stable specification window. |
| Ongoing (2025-2027) | CEP 2.0 rollout continues | EDQM processes CEP conversions progressively. Holders should submit updates at next scheduled revision. |
| Earliest 2027 | Potential next UDCA monograph revision | No confirmed date. Earliest opportunity would be Supplement 12.4 or Ph. Eur. 13th Edition. Monitor EDQM publications. |
For practical compliance planning: CEP holders have a stable window through at least the end of 2026 to submit their next revision incorporating the 12th Edition specification. The absence of UDCA from Supplement 12.3 means no mid-year surprises — the next confirmed checkpoint is Supplement 12.4, expected in 2027.